Imagine Pharma

Executive Summary

Imagine Pharma is a private biotechnology company headquartered in Philadelphia, founded in 2011, with a mission to transform patient care through three proprietary platforms: Oral Delivery for biologics, Therapeutics for novel treatments, and Regenerative Medicine for tissue and cell repair. The company aims to make injections obsolete by developing oral formulations of biologics, cure diseases like diabetes, and accelerate wound healing. While the company has not disclosed specific pipeline candidates or funding details, its focus on first-in-class therapies addresses significant unmet medical needs and has potential for high impact. Given its early stage, Imagine Pharma's progress likely hinges on advancing preclinical programs toward clinical trials and securing partnerships or funding. Key upcoming catalysts include the filing of an Investigational New Drug (IND) application for an oral biologic candidate targeting diabetes, initial clinical data from its regenerative medicine program for wound healing, and potential strategic alliances with larger pharmaceutical companies to leverage its oral delivery platform. Success in these areas could validate the technology and drive value, though the lack of public financials and pipeline details limits visibility.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Oral Biologic (Diabetes)40% success
• Q4 2026Phase 1 Data for Wound Healing Product35% success
• H1 2027Strategic Partnership for Oral Delivery Platform50% success